RecruitingEarly Phase 1NCT03107520

Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH

Use of Intraoperative Contrast-enhanced Ultrasound to Evaluate Femoral Head Perfusion in Infants With Developmental Dysplasia of the Hip at the Time of Surgical Reduction

Sponsor

Children's Hospital of Philadelphia

Enrollment

125 participants

Start Date

May 22, 2017

Study Type

INTERVENTIONAL

Conditions

Developmental Dysplasia of the Hip

Summary

This study evaluates the feasibility and utility of contrast-enhanced ultrasound to provide real-time assessment of blood flow to the femoral head in infants undergoing surgical reduction for developmental dysplasia of the hip.

Eligibility

Min Age: 4 MonthsMax Age: 24 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Intraoperative contrast-enhanced ultrasound (CEUS) and a drug called Lumason for people with developmental dysplasia of the hip. The study is currently recruiting participants at 1 location. People eligible for this study include aged 4 Months to 24 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTIntraoperative contrast-enhanced ultrasound (CEUS)

An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.

DRUGLumason

Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.